Medicine and Dentistry
Gilvetmab
100%
Immune Checkpoint Inhibitor
100%
Pancreas Cancer
100%
Chimeric Antigen Receptor
100%
Chimeric Antigen Receptor T-Cell
100%
Programmed Death-Ligand 1
71%
T Cell
57%
Cancer Cell
28%
In Vitro
28%
Neoplasm
28%
Survival Rate
28%
Cytokine
28%
Cytotoxicity
28%
Cancer
28%
Pancreatic Cancer
28%
Malignant Neoplasm
14%
Antigen Receptor Signaling
14%
Immunosuppressive Treatment
14%
Tumor Cell
14%
Pancreas Adenocarcinoma
14%
Effector Cell
14%
Lung Cancer
14%
B Cell
14%
T Lymphocyte Receptor
14%
Clinical Trial
14%
Homeostasis
14%
Antigen Specificity
14%
Therapy Effect
14%
Solid Malignant Neoplasm
14%
Tumor Microenvironment
14%
Programmed Death 1 Ligand 1
14%
Immunological Tolerance
14%
T-Cell Signaling
14%
Tumor Xenograft
14%
Immunotherapy
14%
Monoclonal Antibody
14%
CD3 Antigen
14%
Diseases
14%
Immunology and Microbiology
Gilvetmab
100%
Chimeric Antigen Receptor
100%
Chimeric Antigen Receptor T-Cell
100%
Programmed Death-Ligand 1
71%
T Cell
57%
Cytotoxicity
28%
Survival Rate
28%
Cytokine
28%
Cancer Cell
28%
Antigen Specificity
14%
Homeostasis
14%
Tumor Cell
14%
T-Cell Signaling
14%
Mouse Model
14%
Transgenics
14%
Antigen Receptor Signaling
14%
CD3 Antigen
14%
Programmed Death 1 Ligand 1
14%
Immune Tolerance
14%
Effector Cell
14%
B Cell
14%
Immunotherapy
14%
CD28
14%
Xenograft
14%
Monoclonal Antibody
14%
T Cell Receptor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Immune Checkpoint Inhibitor
100%
Gilvetmab
100%
Chimeric Antigen Receptor
100%
Neoplasm
36%
Malignant Neoplasm
18%
Cytokine
18%
Elimination
18%
Survival Rate
18%
Cytotoxicity
18%
Pancreas Adenocarcinoma
9%
T Lymphocyte Receptor
9%
Immunotherapy
9%
Mouse Model
9%
CD3 Antigen
9%
Tumor Microenvironment
9%
Therapeutic Effect
9%
Solid Malignant Neoplasm
9%
Lung Cancer
9%
Programmed Death 1 Ligand 1
9%
Clinical Trial
9%
Monoclonal Antibody
9%
Diseases
9%